Saturday, 31 July 2021 10:57 GMT

MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call


( MENAFN - GlobeNewsWire - Nasdaq RO)CKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter 2021 after the market closes on Thursday, July 29, 2021. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, July 29, 2021 at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 7983402.

The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at  . A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc. 


Tags Biopharmaceuticals BIOTECHNOLOGY CONFERENCE CALL EARNINGS MacroGenics ONCOLOGY WEBCAST PHARMACEUTICALS Contact Data CONTACTS: Christopher James, M.D., Vice President, Investor Relations and Corporate Communications Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, Contact close Contact With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!


Already have an account? Log in here.

MENAFN22072021004107003653ID1102494364


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.